CD226 deficiency or blocking with anti-CD226 mAbs rendered tumor-bearing mice resistant to the combined treatment, which implies that CD226 is required for the efficacy of anti-PD-1 and anti-GITR mAb combination treatment. Here, CD226 is linked to neoplasm.